Oral News and Research

RSS

Fatty acids in nuts help reduce risk of CHD in people with type 2 diabetes

Findings from a new study published in Nutrition, Metabolism & Cardiovascular Diseases show that the fatty acids in nuts have the potential to help reduce the risk of coronary heart disease (CHD) in people with type 2 diabetes.

25 Jun 2014

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases.

24 Jun 2014

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance-the body's response to consuming carbohydrates- after four weeks of treatment and without a change in diet.

24 Jun 2014

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year.

24 Jun 2014

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena, Inc. (NASDAQ:TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids.

23 Jun 2014

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology, Inc. announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site.

23 Jun 2014

Bisexual men are vulnerable to STIs and other health problems

Bisexual men have many unmet public health needs, which leave them vulnerable to sexually transmitted infections (STIs) and other health problems. This new study from the Centers for Disease Control and Prevention (CDC) illuminates the behavioral, interpersonal, and social realities of men who have sex with men and women (MSMW), and it explores possible interventions to better serve their needs.

23 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Greenlander study identifies single mutation with large diabetes risk

Researchers have used a Greenlandic cohort to identify a genetic mutation whose effect on the risk of diabetes is “several times larger” than any previously discovered.

20 Jun 2014

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.

20 Jun 2014

Arthritis drug promotes hair growth in hairless man

A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University.

20 Jun 2014

High Court decision imminent on health law's birth control mandate

Also pending is a decision regarding free speech arguments against a Massachusetts law that creates a buffer zone around abortion clinics to keep protesters from patients.

20 Jun 2014

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis.

20 Jun 2014

First Edition: June 19, 2014

Today's headlines include reports about how the 2015 insurance premium rates are shaping up across the country and details of consumers' experiences in trying to get their new coverage.

19 Jun 2014

Review on effects of treating cholera with antimicrobial drugs

Researchers from the Cochrane Infectious Diseases Group, co-ordinated through the editorial base in LSTM, conducted an independent review of the effects of treating cholera with antimicrobial drugs, published in The Cochrane Library today.

19 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

The National Institutes of Health has awarded a four-year, $3.7 million grant to researchers at the University of Maryland School of Medicine to develop a personalized medicine program to help doctors diagnose and treat monogenic diabetes - a form of diabetes caused by a mutation in a single gene.

19 Jun 2014

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.

18 Jun 2014

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Oral News and Research

Fatty acids in nuts help reduce risk of CHD in people with type 2 diabetes

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Bisexual men are vulnerable to STIs and other health problems

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Greenlander study identifies single mutation with large diabetes risk

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Arthritis drug promotes hair growth in hairless man

High Court decision imminent on health law's birth control mandate

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

First Edition: June 19, 2014

Review on effects of treating cholera with antimicrobial drugs

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

U of MD researchers to use $3.7 million NIH grant to develop novel method to treat monogenic diabetes

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

New approach promises better drugs for diabetes and osteoporosis

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News